NCT02746237已完成1 期
A Randomized, Double-blind, Placebo-controlled, Phase 1, First-in-human, Single-center, Safety, Tolerability, Ventricular Repolarization and Pharmacokinetic Study of Single and Multiple Ascending Doses of KAR5585 in Healthy Subjects
Karos Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2015年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Number of participants with abnormal hematology values
研究概览
简要总结
Safety, tolerability, pharmacokinetics (PK), cardiac conduction and food effect study on single and multiple ascending doses of KAR5585 in healthy adults.
详细描述
The purpose of this study is to explore the safety, tolerability, pharmacokinetics (PK), and cardiac conduction effects of single and multiple ascending doses of KAR5585 in healthy adults. Food effect will also be evaluated after a single-dose administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject is able to read, write, and comprehend English at a sufficient level to understand study-related materials
- •Subject is able to provide written informed consent and to comply with all study requirements and restrictions
- •Subject is male or female and aged 18 to 65 years, inclusive, at the time of informed consent
- •Subject is in good health as determined by the PI based on detailed medical history, physical examination, vital signs, clinical laboratory tests, ECGs, and other pre-dose evaluations
- •Subject agrees to use a medically acceptable form of birth control from CRU admission until at least 30 days (female subject) or 90 days (male subject) after the last dose of study drug. Males will also not donate sperm from CRU admission until at least 90 days after the last dose of study drug. If a subject is not sexually active but becomes active during study participation, the subject agrees they and their partner will use a medically accepted form of contraception for the time specified. Medically acceptable forms of contraception are:
- •FDA-approved female hormonal contraceptives used consistently for 2 or more cycles before Screening, including oral contraceptives, intrauterine device (IUD), medroxyprogesterone acetate injection (Depo Provera®), hormonal implant (Norplant®, Implanon®, Nexplanon®), and vaginal ring (NuvaRing®)
- •Male condom plus spermicide
- •Male condom plus contraceptive sponge, foam, or jelly
- •Female condom plus spermicide
- •Diaphragm with spermicide plus male condom
- •Cervical cap with spermicide plus male condom
- •Surgical sterilization of the subject or partner (vasectomy for males, hysterectomy or bilateral oophorectomy for females)
- •Abstinence
- •If female, subject agrees that a serum pregnancy test ([β hCG] beta human chorionic gonadotropin ) will be performed at Screening, on Day 2 (CRU admission), and at the last study visit and negative test results at Screening and CRU admission are required to be considered for study participation
- •Subject has a body mass index (BMI) of 20 to 35 kg/m2, inclusive, and body weight < 120 kg at Screening
排除标准
- •Subject currently uses tobacco or nicotine-containing products or has used such products within 6 months before CRU admission
- •Subject has history or current evidence of any clinically significant cardiac, endocrinologic, hematologic, hepatobiliary, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease, as determined by the PI
- •Subject has a history of cancer within 5 years before CRU admission (excluding non-melanoma skin cancer)
- •Subject has a history of autonomic dysfunction (eg, history of repeated dizziness, fainting, or symptomatic orthostatic hypotension)
- •Subject has a history of risk factors for torsades de pointes, including unexplained syncope, known long QT syndrome, heart failure, myocardial infarction, angina, OR clinically significant abnormal laboratory assessments including hypokalemia, hypomagnesemia, or hypercalcemia OR has a family history of long QT syndrome or Brugada syndrome
- •Subject has 1 or more clinically significant abnormal laboratory test values (as determined by the PI)
- •Subject has an uninterpretable or abnormal screening ECG indicating a second- or third-degree atrioventricular block, or 1 or more of the following: QRS interval (ventricular depolarization) > 110 msec; a PR interval (atrioventricular conduction) > 220 msec, or QTc (corrected QT interval) of ≥ 450 msec (for male) or ≥ 470 msec (for female) or any rhythm other than sinus rhythm that is interpreted by the PI or a qualified designee to be clinically significant
- •Subject has a resting heart rate (HR) of < 40 beats/min or > 90 beats/min at Screening or on CRU admission
- •Subject has a sustained supine systolic blood pressure (BP) > 155 or < 90 mm Hg or a supine diastolic BP > 95 or < 50 mm Hg at Screening or upon CRU admission. Blood pressure in the supine position may be retested once and 'sustained' is defined as the parameter (either systolic or diastolic BP) being outside the stated limits at both assessments.
- •Subject participates in another clinical trial or treatment with an investigational agent within 30 days or 5 half-lives, whichever is longer, before CRU admission
- •Subject has a history of alcohol or drug abuse or dependence within 12 months before CRU admission, as determined by the PI
- •Subject has a clinically significant infection within 3 months before CRU admission, as determined by the PI
- •Subject has any condition that, in the opinion of the PI, would make the subject unsuitable for enrollment or could interfere with the subject's participation in or completion of the study
- •Subject has a positive urine screen for prohibited drugs (cocaine, cannabinoids, nicotine [urine cotinine is the detection mechanism for nicotine], opiates, barbiturates, amphetamines, and benzodiazepines) or positive urine test for alcohol
- •Subject has a positive blood screen for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus antibody at the Screening Visit
- •Subject has had a known or suspected hypersensitivity or idiosyncratic reaction to the cellulose used in the placebo to be used in this study
- •Subject has donated blood or any blood products within 3 months before Screening or plans to donate blood during or within 3 months after study completion
- •Subject consumes an excessive amount of caffeine daily, defined as > 4 cups of coffee or equivalent per day. Subjects will abstain from caffeine consumption for 48 hours before dosing and while confined to the CRU.
- •Subject has consumed or will consume any concomitant therapy; prescription or over-the-counter (OTC) medication; or nutritional, herbal, or vitamin supplements other than contraceptives (eg, oral, systemic) and ibuprofen (only if needed, maximum 2.4 g/day) from 14 days or 5 half-lives (whichever is longer) before dosing and while confined to the CRU
- •For Part 2 only: Subject has consumed any food, juice, beverage, or medication (prescription or non-prescription) containing acetaminophen, alcohol, avocado, banana, caffeine, eggplant, kiwi fruit, nut (hickory nut, pecan, walnut), pineapple, plum, or tomato products within 48 hours before CRU admission
研究组 & 干预措施
KAR5585
Experimental
KAR5585 Capsules
干预措施: KAR5585 Capsules (Drug)
Placebo
Placebo Comparator
Placebo capsules
干预措施: Placebo Capsules (Drug)
结局指标
主要结局
Number of participants with abnormal hematology values
时间窗: From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses
Healthy adult volunteers receiving single and multiple doses of KAR5585 administered orally will be monitored for adverse events via lab evaluation of hematology.
Number of participants with abnormal clinical chemistry values
时间窗: From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses
Healthy adult volunteers receiving single and multiple doses of KAR5585 administered orally will be monitored for adverse events via lab evaluation of clinical chemistries.
Number of participants with abnormal urinalysis values
时间窗: From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses
Healthy adult volunteers receiving single and multiple doses of KAR5585 administered orally will be monitored for adverse events via lab evaluation of urinalysis.
Number of participants with abnormal electrocardiogram results
时间窗: From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses
Healthy adult volunteers receiving single and multiple doses of KAR5585 administered orally will be monitored for abnormal ECG results.
Number of participants with abnormal physical exam results
时间窗: From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses
Healthy adult volunteers receiving single and multiple doses of KAR5585 administered orally will be monitored for adverse events via physical examination.
次要结局
- Apparent volume of distribution (Vz/F) of prodrug KAR5585 and active inhibitor KAR5417(From 0-24hrs on Days 1, 7 and 14)
- Plasma terminal elimination half-life (T1/2) of prodrug KAR5585 and active inhibitor KAR5417(From 0-24hrs on Days 1, 7 and 14)
- Plasma area under the curve (AUC0-24) of prodrug KAR5585 and active inhibitor KAR5417 from time zero to 24 hours after dosing(From 0-24hrs on Days 1, 7 and 14)
- Time to reach maximum observed plasma concentration (Tmax) of prodrug KAR5585 and active inhibitor KAR5417(From 0-24hrs on Days 1, 7 and 14)
- Plasma terminal elimination half- life (T1/2) of prodrug KAR5585 and active inhibitor KAR5417(From 0-24 hours on Days 1, 7 and 14)
- Maximum peak concentration (Cmax) of prodrug KAR5585 and active inhibitor KAR5417(From 0-24hrs on Days 1, 7 and 14)
- Urinary levels of creatinine (gm/24 hrs)(From 0-24 hours on Days 1, 7 and 14)
- Urinary levels of 5-hydroxyindoleacetic acid normalized to creatinine (mg/gm)(From 0-24 hours on Days 1, 7 and 14)
- Serum levels of serotonin (ng/mL)(Days 1, 7 and 14)
- Urinary levels of 5-hydroxyindoleacetic acid(mg/24 hrs)(From 0-24 hours on Days 1, 7 and 14)
- Plasma levels of 5-hydroxyindoleacetic acid (ng/mL)(Days 1, 7 and 14)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
The Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of BWC0977 in Healthy Adult VolunteersInfectious DiseasesBacterial InfectionsNCT05942820Bugworks Research Inc.4
已完成
1 期
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy VolunteersInfectious DiseasesBacterial InfectionsNCT05088421Bugworks Research Inc.44
已完成
1 期
Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged VolunteersAlzheimer DiseaseNCT04074837Neuronascent, Inc.56
已完成
1 期
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy VolunteersHealthy VolunteersNCT03792308Spero Therapeutics94
已完成
1 期
Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy SubjectsRheumatoid ArthritisNCT02705989Bristol-Myers Squibb439